Laura G. Eichorn - Dec 15, 2022 Form 4 Insider Report for Imago BioSciences, Inc. (IMGO)

Role
Chief Financial Officer
Signature
/s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn
Stock symbol
IMGO
Transactions as of
Dec 15, 2022
Transactions value $
-$4,255,357
Form type
4
Date filed
12/19/2022, 03:10 PM
Previous filing
Nov 14, 2022
Next filing
Dec 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGO Common Stock Options Exercise $37.8K +18K +8.66% $2.10* 226K Dec 15, 2022 Direct
transaction IMGO Common Stock Options Exercise $6.52K +2.98K +1.32% $2.19* 229K Dec 15, 2022 Direct
transaction IMGO Common Stock Options Exercise $5.4K +2.38K +1.04% $2.27* 231K Dec 15, 2022 Direct
transaction IMGO Common Stock Options Exercise $184K +73K +31.59% $2.52* 304K Dec 15, 2022 Direct
transaction IMGO Common Stock Options Exercise $46.2K +30.4K +9.99% $1.52* 334K Dec 15, 2022 Direct
transaction IMGO Common Stock Sale -$4.54M -127K -37.89% $35.79 208K Dec 15, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -18K -60.41% $0.00 11.8K Dec 15, 2022 Common Stock 18K $2.10 Direct F2
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -2.98K -100% $0.00* 0 Dec 15, 2022 Common Stock 2.98K $2.19 Direct
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -2.38K -100% $0.00* 0 Dec 15, 2022 Common Stock 2.38K $2.27 Direct
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -73K -73.7% $0.00 26.1K Dec 15, 2022 Common Stock 73K $2.52 Direct
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -30.4K -87.81% $0.00 4.22K Dec 15, 2022 Common Stock 30.4K $1.52 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was executed in multiple trades in prices ranging from $35.78 to $35.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F2 The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F3 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger, by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. In connection with the Merger, to mitigate the potential impact of Section 280G and Section 4999 of the Internal Revenue Code of 1986, as amended, the Reporting Person entered into the transactions disclosed on this Form 4.